BioSeek EPA ToxCast Program
Upcoming SlideShare
Loading in...5
×
 

BioSeek EPA ToxCast Program

on

  • 4,157 views

Summary of BioSeek's work for the EPA's ToxCast (TM) program. BioSeek has been a contractor since 2007 for the EPA, using the company's human cell-based BioMAP(R) systems platform.

Summary of BioSeek's work for the EPA's ToxCast (TM) program. BioSeek has been a contractor since 2007 for the EPA, using the company's human cell-based BioMAP(R) systems platform.

Statistics

Views

Total Views
4,157
Views on SlideShare
919
Embed Views
3,238

Actions

Likes
0
Downloads
13
Comments
0

1 Embed 3,238

http://biomapsystems.com 3238

Accessibility

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    BioSeek EPA ToxCast Program BioSeek EPA ToxCast Program Presentation Transcript

    • BioSeek – EPA ToxCastTM Program Bridging the Gap From In Vitro to In Vivo1
    • EPA ToxCastTM Program  EPA ToxCastTM Program  Program to develop a cost-effective approach for efficiently prioritizing the toxicity testing of thousands of chemicals  BioSeek has been a contractor since 2007  Three Phases  Phase I – Proof-of-concept  Phase II – Verification / Extension  Phase III – Reduction to Practice  http://www.epa.gov/ncct/toxcast/2
    • ToxCastTM Program Timeline3
    • ToxCastTM Program Details Number of Chemical Number of Cost per Target Phase Purpose Chemicals Criteria Assays Chemical Date Data Rich Signature I 320 552 $20k FY08 (pesticides) Development Ib 15 Nanomaterials Pilot 166 $10K FY09 Data Rich IIa >300 Validation >400 ~$20-25k FY09 Chemicals Known Human IIb >100 Extrapolation >400 ~$20-25k FY09 Toxicants Expanded Structure IIc >300 Extension >400 ~$20-25k FY10 and Use Diversity IId >12 Nanomaterials PMN >200 ~$15-20K FY09-10 Prediction and III Thousands Data poor >300 ~$15-20k FY11-12 Prioritization7/23/2012 CONFIDENTIAL4
    • BioSeek ToxCastTM Data Now Posted on EPA’s ACToR Public Database http://actor.epa.gov/ ACToR Aggregated Computational Toxicology Resource5
    • BioMAP® Analysis of ToxCastTM Phase I Chemicals Diversity of Mechanisms Distinguished NFB cAMP Elevation DNA Alkylation Mitochondrial DysfunctionReference: Houck, K.A., D.J. Dix, R.S. Judson, R.J. Kavlock, J.Yang and E.L. Berg. 2009. Profiling bioactivity of the ToxCast Tubulin Inhibitionchemical library using BioMAP primary human cell systems. J.Biomol. Screen, 2009, 14:1054-66.6
    • BioMAP Endpoints (BSK) in Predictive Signatures Rat & Rabbit Developmental Toxicity Knudsen, T.B., Computational Toxicology and Prenatal Development, presentation for the EPAs Computational Toxicology Community of Practice (8/25/2011)7 Toxicol Sci. 2011, 124:109-27
    • BioMAP® Analysis of Nanomaterials ToxCast Phase II Chemicals • Nanomaterials are active and distinguishable by composition • Reference: Wang, A., E.L. Berg, M. Polokoff, J. Yang; D. Reif, N. Kleinstreuer, S. Marinakos, A.R. Badireddy, S. Gangwal, C. Matson, M. Wiesner, and K. Houck. Nanomaterial (NM) bioactivity profiling by ToxCast high- throughput screening (HTS). Society of Toxicology Annual Meeting, March 12, 2012, San Francisco, CA.8 Confidential
    • BioMAP® Profile of Titanium Oxide Nanoparticles Similarity to Paclitaxel • Paclitaxel – binds b-tubulin and causes microtubule stabilization • TiO2 nanoparticles interfere with microtubules (PMID: 18776989)9 Confidential
    • BioMAP® Analysis of Failed Pharma Compounds  Nicole Kleinstreuer, Society of Toxicology Annual Meeting, March 12, 2012, San Francisco, CA10
    • Publications with BioSeek ToxCastTM Data Sipes NS, Martin MT, Reif DM, Kleinstreuer NC, Judson RS, Singh AV, Chandler KJ, Dix DJ, Kavlock RJ, Knudsen TB. Predictive models of prenatal developmental toxicity from ToxCast high-throughput screening data. Toxicol Sci. 2011, 124:109-27 Knudsen, T. B., K. A. Houck, N. Sipes, A. V. Singh, R. Judson, M. T. Martin, A. Weissman, N. Kleinstreuer, H. M. Mortensen, D. Reif, J. R. Rabinowitz, R. W. Setzer, A. M. Richard, D. J. Dix, And R. J. Kavlock. Activity profiles of 309 ToxCast™ chemicals evaluated across 292 biochemical targets. TOXICOLOGY. Elsevier Ireland Limited, Limerick, Ireland, 282(1-2):1-15, (2011). Kleinstreuer, N. C., R. S. Judson, D. M. Reif, N. S. Sipes, A. V. Singh, K. J. Chandler, R. Dewoskin, D. J. Dix, R. J. Kavlock, And T. B. Knudsen. Environmental Impact on Vascular Development Predicted by High Throughput Screening. ENVIRONMENTAL HEALTH PERSPECTIVES. National Institute of Environmental Health Sciences (NIEHS), Research Triangle Park, NC, Online Edition:1-34, (2011). doi:10.1289/ehp.1103412 Houck, K.A., D.J. Dix, R.S. Judson, R.J. Kavlock, J. Yang and E.L. Berg. 2009. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J. Biomol. Screen, 2009, 14:1054-66. Judson RS, Houck KA, Kavlock RJ, Knudsen TB, Martin MT, et al. 2009, In Vitro Screening of Environmental Chemicals for Targeted Testing Prioritization: The ToxCast Project. Environ Health Perspect 118(4): doi:10.1289/ehp.090139211
    • Presentations with BioSeek ToxCastTM Data Kleinstreuer, N. C., vEmbryo in silico models:Predicting vascular developmental toxicity, Wiley- Blackwell Symposium on Computational Embryology: Integration and Modeling of Developmental Mechanisms, Teratology Society 2012, June 25, 2012, Baltimore, MD. Wang, A., E.L. Berg, M. Polokoff, J. Yang; D. Reif, N. Kleinstreuer, S. Marinakos, A.R. Badireddy, S. Gangwal, C. Matson, M. Wiesner, and K. Houck. Nanomaterial (NM) bioactivity profiling by ToxCast high-throughput screening (HTS). Society of Toxicology Annual Meeting, March 12, 2012, San Francisco, CA. Kleinstreuer, N. C., K. Houck, R. Judson, D. Reif, P. Kothiya, M. Martin, T. Knudsen, A. Richard, M. Polokoff, J. Yang, E.L. Berg, R. Kavlock, and D. Dix. Biological profiling of the ToxCast Phase II Chemical Library in Primary Human Cell CoCulture Systems. Society of Toxicology Annual Meeting, March 12, 2012, San Francisco, CA. Houck, K., Use of primary human cell systems for creating predictive toxicology profiles. SBS Annual Meeting, 2009, Lille, France. Houck, K. Evaluation of the ToxCast™ suite of cellular and molecular assay for prediction of in vivo toxicity. GlobalChem, 2009, Baltimore, MD. Houck, K., Characteristics of the ToxCast™ In Vitro Datasets from Biochemical and Cellular Assays (EPA/ORD/NCCT). ToxCast™ Data Analysis Summit, May 14, 2009, RTP, NC.12
    • Contacts BioSeek, LLC 310 Utah, Suite 100 South San Francisco, CA 94030 650-416-7600 www.bioseekinc.com www.BioMAPSystems.com Bridging the Gap From In Vitro to In VivoBioSeek, LLC310 Utah, #100South San Francisco, CA 94080